Benitec Biopharma Financials - Benzinga

Benitec Biopharma Inc

BNTCNASDAQ

Trade with Public

Trade with Public

$10.02

0.434.48%

al cierre: Sep 28, 5:00 PM EST

$9.86

-0.16-1.6%

After hour: Sep 25, 4:01 PM EST

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Benitec Biopharma Financials

Benitec Biopharma (BNTC) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Benitec Biopharma Q4 EPS $(0.26), Inline

Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 38.1 percent increase over losses of $(0.42) per share from the same period last year.

Benzinga Newsdesk

PRO
Benitec Biopharma Q3 EPS $(0.24) Beats $(0.27) Estimate

Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 36.84 percent increase over losses of $(0.38) per share from

Benzinga Newsdesk

PRO
Benitec Biopharma Q2 EPS $(0.26) Misses $(0.22) Estimate

Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.22) by 16.59 percent. This is unchanged from the same period last year.

Benzinga Newsdesk

PRO
Benitec Biopharma Q1 EPS $(0.22) Beats $(0.41) Estimate

Benzinga Newsdesk

PRO
CORRECTION: Benitec Biopharma Q4 EPS $(0.42) Misses $(0.33) Estimate

Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.33) by 25.75 percent. This is a 30 percent increase over losses of $(0.60) per share from

Benzinga Newsdesk

PRO
Benitec Biopharma Q3 EPS $(0.24) Beats $(0.35) Estimate

Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.35) by 31.43 percent. This is a 85.37 percent increase over losses of $(1.64) per share from

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved